Nicotine delivered via an e-cigarette — Competitive Intelligence Brief

Nicotine delivered via an e-cigarette (Nicotine delivered via an e-cigarette) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist. Area: Smoking Cessation / Addiction Medicine.

phase 3 Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors (nAChR) Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

Nicotine delivered via an e-cigarette (Nicotine delivered via an e-cigarette) — University of Auckland, New Zealand. Nicotine acts as a nicotinic acetylcholine receptor agonist, binding to and activating these receptors in the central and peripheral nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine delivered via an e-cigarette TARGET	Nicotine delivered via an e-cigarette	University of Auckland, New Zealand	phase 3	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors (nAChR)
Nicorette Gum	Nicorette Gum	University of Miami	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine Transdermal Patch	Nicotine Transdermal Patch	University of Southern California	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine Replacement Therapy	Nicotine Replacement Therapy	Ottawa Hospital Research Institute	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine rescue method	Nicotine rescue method	VA Office of Research and Development	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors (α4β2 and other subtypes)
Nicotine (4 mg)	Nicotine (4 mg)	GlaxoSmithKline	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Motivation-Phase Nicotine Mini-Lozenge	Motivation-Phase Nicotine Mini-Lozenge	VA Office of Research and Development	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acetylcholine receptor agonist class)

1. University of Wisconsin, Madison · 3 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. VA Office of Research and Development · 2 drugs in this class
4. Iowa City Veterans Affairs Medical Center · 1 drug in this class
5. Johns Hopkins University · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. 22nd Century Group, Inc. · 1 drug in this class
8. University of Auckland, New Zealand · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Miami · 1 drug in this class